By Colin Kellaher Shares of OpGen surged more than sixfold in premarket trading Thursday after the precision-medicine company said it was in talks on a.
Equities researchers at StockNews.com initiated coverage on shares of Precigen (NASDAQ:PGEN – Get Free Report) in a research note issued to investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock. Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Precigen in a research […]
StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a hold rating on the medical research company’s stock. Separately, HC Wainwright downgraded shares of OpGen from a buy rating to a neutral rating in a research report on Monday, August 14th. […]
OpGen (NASDAQ:OPGN – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, profitability, analyst recommendations and dividends. Analyst Ratings This is a summary of recent ratings […]
StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a research note published on Sunday. The firm issued a hold rating on the medical research company’s stock. Separately, HC Wainwright cut OpGen from a buy rating to a neutral rating in a research report on Monday, August 14th. Read Our Latest Analysis […]